Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

A Randomized, Open and Control Clinical Study of Endostar Injection Concomitant With SOX Protocols in Treating Advanced Gastric Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02008422
• Other study ID #: XinjiangMU (006)
• Status: Active, not recruiting
• Phase: Phase 3
• First received: November 27, 2013
• Last updated: December 6, 2013
• Start date: August 2013
• Est. completion date: August 2016

Study information

• Verified date: August 2013
• Source: Xinjiang Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objectives of this control, single-center clinical study of EndostarTM Injection with/without SOX protocols to treat advanced gastric cancer were to evaluate the clinical response rate of Endostar injection concomitant with SOX on patients with advanced gastric cancer, observe the progression-free survival time (PFS) of tumor and evaluate the safety and tolerance of Endostar injection, while the secondary objectives were to observe the influence of Endostar injection on chemotherapy-induced adverse reactions and evaluate the overall survival time of EndostarTM injection concomitant with SOX on patients with advanced gastric cancer by evaluating the response rate (RR) clinical benefit rate (CBR), progression-free survival (PFS) and overall survival (OS).

Description:

Multiple pre-clinical studies have indicated that in dozens of animal tumor models and human tumor-metastatic mice tumor models, the effective rate of Endostar was 47%～91% in daily dosage of 10～100mg/kg, and covered human commonly seen malignant tumors, such as lung cancer, gastric cancer, breast cancer, colorectal cancer, hepatic cancer, malignant melanoma and non-Hodgkin's lymphoma, etc.. The development and progression of gastric cancer was in association with angiogenesis. An animal research observed the influence of Endostar on tumor strains in nude mice with gastric cancer, and the results showed that tumor size shrunk rapidly and the expressions of VEGF, bFGF, VEGF-C, VEGFR-3, bcl-2 and PDGF decreased significantly after treatment in experimental group, demonstrating that Endostar could reduce angiogenesis, increase tumor cell apoptosis and inhibit tumor growth in gastric cancer. An investigation of small-sample Endostar concomitant with chemotherapy on patients with advanced gastric cancer primarily indicated the efficacy and feasibility of Endostar concomitant with chemotherapy in treating gastric cancer.

With the expanded application of Endostar in clinic, it also obtains certain effect in treating patients with lung cancer and colorectal cancer. The safety, efficacy, evaluation of relationship between benefit and risk in common or special population as well as the modified dosage of administration of Endostar in wide application should be further explored to provide sufficient scientifical basis for the safety, efficacy, applicable rule in special population and investigation of optimal administrative protocols for Endostar in wide application.

This control, single-center clinical study of EndostarTM Injection with/without SOX protocols to treat advanced gastric cancer was conducted to explore the feasibility, efficacy and safety of Endostar concomitant with SOX protocols, and to provide more evidence-based medical basis for the clinical application of Endostar.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 120
• Est. completion date: August 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age: 18~70 years;

• Performance status (PS) of Eastern Cooperative Oncology Group (ECOG) was 0~1 or KPS scores were 60-100 scores;

• Patients who were diagnosed with recurrent and metastatic advanced gastric cancer by histopathology and CT;

• Patients who had more than 1 measurable nidus (common CT or MRI scanning =20 mm, spiral CT scanning =10 mm);

• Patients who had no severe dysfunction of important organs, and were normal in blood routine test, hepatorenal function, electrolytes and cardiac function, with white blood cell count=4.0×109/L, neutrophil count=1.5×109/L, platelet count=100×109/L, hemoglobin=95g/L, serum bilirubin=1.5 folds of upper normal limit, Alanine transaminase and glutamic oxalacetic transaminase =2 folds of upper normal limit, and serum creatinine=1.5mg/dl.

• Estimated survival time was above 3 months;

• Patients who were well acknowledged of this study and signed the informed consent forms.

Exclusion Criteria:

• Patients who received whole body treatment of metastatic gastric cancer previously;

• Patients who underwent surgeries within 4 weeks before this study;

• Patients who had allergic constitutions or were allergic to biological products of proteins and to any medicine used in this study;

• Female patients in gestation or lactation period, or those who were interfile but received no contraception measures;

• Patients who were with other symptoms unsuitable to this study;

• Patients who were treated by other anti-tumor methods at that time;

• Patients who had no measurable nidus;

• Patients who had one of the following conditions: uncontrolled metastatic nidus in central nervous system, dysfunction of important organs, severe cardiac diseases (including congestive heart failure, uncontrollable arrhythmia, angina pectoris needed long-term drug treatment, valvular heart diseases and myocardial infarction), hypertension, women in gestation or lactation period, protracted infectious wound as well as uncontrollable psychosis history.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Oxaliplatin
130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
• Gimeracil and Oteracil Potassium Capsule
40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
• Endostar injection
7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.

Locations

Country	Name	City	State
China	Cancer Hospital of Xinjiang Medical University	Urumqi	Xinjiang

Sponsors (1)

Lead Sponsor	Collaborator
Tang Xushan

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rate (RR)	Clinical RR=(CR+PR)/total cases×100%; Complete remission (CR): all visible nidi disappeared; Partial remission (PR): the decreased total length of diameter of baseline nidus=30%;	The patients were followed up for 3 years.	No
Primary	clinical benefit rate (CBR)	Clinical CBR=(CR+PR+SD)/total cases×100%; Complete remission (CR): all visible nidi disappeared; Stable disease (SD): the total length of diameter of baseline nidus decreased	The patients were followed up for 3 years.	No
Primary	progression-free survival (PFS)	PFS was from randomization to tumor progression or death.	The patients were followed up for 3 years	No
Secondary	overall survival (OS)		The patients were followed up for 3 years	No